RecruitingGeneralized Anxiety Disorder
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Eligible age
18–74 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Sponsor: Reunion Neuroscience Inc
You may qualify if…
- ✓ Has Generalized Anxiety Disorder as defined by DSM-5-TR
- ✓ If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
- ✓ Is willing and able to comply with the conditions and requirements of the study
You may not qualify if…
- ✕ Has a significant risk of suicide
- ✕ Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- ✕ Has other concurrent psychiatric disorders that is the primary disorder.
- ✕ Has other medically significant conditions rendering unsuitability for the study
- ✕ Has used or will need to use prohibited medications or therapies
- ✕ Has a known sensitivity or intolerance to study intervention or potential rescue medications
Where it's recruiting
Arizona
Gilbert
California
San Francisco · Santa Monica
Florida
Tampa
Georgia
Atlanta · Decatur
New Mexico
Albuquerque
Oregon
Portland
Texas
Austin · Plano
Utah
Draper · Orem
Source: ClinicalTrials.gov · NCT07489651 · last updated 2026-05-18